Research and Markets has released its report for the Chinese Pharmaceutical Equipment industry for 2013 -2016. According to the analysis, revenue is expected to hit Rmb 53.22 billion in 2016, but the market will slow down in the next two years.
The report entitled "Concise Analysis of the Chinese Pharmaceutical Equipment Industry" stated that both revenue and total profit of China’s pharmaceutical equipment industry have experienced significant growth since 2010. Revenue reached a year-on-year growth rate of 51.5%, 28.2% and 26% in 2010-2012 respectively.
The analysis forecasted a more modest revenue growth rate for the industry in 2013 to 2016. Held back by the actual progress seen in new GMP certification and market capacity, the Chinese pharmaceutical equipment industry is expected to reach an annual average growth rate of more or less 20%, with anticipated revenue of RMB 53.22 billion in 2016.
The analysts declared that the market has no single or elite group to dictate growth. “Due to a wide range of pharmaceutical equipment product categories and a customized business model generally adopted by enterprises, there is no one or a few pharmaceutical equipment companies capable of controlling the entire market, the industry concentration is low, the majority of enterprises are small and medium-sized, and the market concentration is low (20%=CR8<40%).”
Several companies were highlighted in the report. These include Shinva Medical Instrument Co., Ltd. as a leading sterilization equipment company (2012 revenue: RMB 2.408 billion), Shanghai Tofflon Science and Technology Co., Ltd. as the top company in the freeze drying system industry (2012 revenue: RMB 822 million), and Truking Technology Ltd. as the major supplier of liquid injection pharmaceutical equipment (2012 revenue: RMB 589 million).
Other companies included in the report are:
The full report is available at Research and Markets.